Literature DB >> 24900837

Iron chelators in photodynamic therapy revisited: synergistic effect by novel highly active thiosemicarbazones.

Anna Mrozek-Wilczkiewicz1, Maciej Serda2, Robert Musiol2, Grzegorz Malecki2, Agnieszka Szurko3, Angelika Muchowicz4, Jakub Golab4, Alicja Ratuszna3, Jaroslaw Polanski2.   

Abstract

In photodynamic therapy (PDT), a noninvasive anticancer treatment, visible light, is used as a magic bullet selectively destroying cancer cells by a photosensitizer that is nontoxic in the dark. Protoporphyrin IX (PpIX) is a natural photosensitizer synthesized in the cell, which is also a chelating agent that if bonded to Fe(2+) forms heme, a central component of hemoglobin. Therefore, xenobiotic iron chelators can disturb iron homeostasis, increasing the accumulation of PpIX, obstructing the last step of heme biosynthesis, and enhancing PDT efficiency. However, the attempts to use this promising idea have not proved to be hugely successful. Herein, we revisited this issue by analyzing the application of iron chelators highly toxic in the dark, which should have higher Fe(2+) affinity than the nontoxic chelators used so far. We have designed and prepared thiosemicarbazones (TSC) with the highest dark cellular cytotoxicity among TSCs ever reported. We demonstrate that compound 2 exerts powerful PDT enhancement when used in combination with 5-aminolevulinic acid (ALA), a precursor of PpIX.

Entities:  

Keywords:  Photodynamic therapy; protoporphyrin IX; reactive oxygen species; thiosemicarbazones; triapine

Year:  2014        PMID: 24900837      PMCID: PMC4027794          DOI: 10.1021/ml400422a

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  25 in total

1.  Enhancement of photodynamic therapy in gastric cancer cells by removal of iron.

Authors:  W C Tan; N Krasner; P O'Toole; M Lombard
Journal:  Gut       Date:  1997-07       Impact factor: 23.059

2.  Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer.

Authors:  Allyson J Ocean; Paul Christos; Joseph A Sparano; Dan Matulich; Andreas Kaubish; Abby Siegel; Max Sung; Maureen M Ward; Nancy Hamel; Igor Espinoza-Delgado; Yun Yen; Maureen E Lane
Journal:  Cancer Chemother Pharmacol       Date:  2010-10-28       Impact factor: 3.333

Review 3.  Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies.

Authors:  Ting-Chao Chou
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

Review 4.  Photodynamic therapy of cancer: an update.

Authors:  Patrizia Agostinis; Kristian Berg; Keith A Cengel; Thomas H Foster; Albert W Girotti; Sandra O Gollnick; Stephen M Hahn; Michael R Hamblin; Asta Juzeniene; David Kessel; Mladen Korbelik; Johan Moan; Pawel Mroz; Dominika Nowis; Jacques Piette; Brian C Wilson; Jakub Golab
Journal:  CA Cancer J Clin       Date:  2011-05-26       Impact factor: 508.702

5.  Continual presence of oxygen and iron required for mammalian ribonucleotide reduction: possible regulation mechanism.

Authors:  L Thelander; A Gräslund; M Thelander
Journal:  Biochem Biophys Res Commun       Date:  1983-02-10       Impact factor: 3.575

6.  Mechanisms involved in delta-aminolevulinic acid (ALA)-induced photosensitivity of tumor cells: relation of ferrochelatase and uptake of ALA to the accumulation of protoporphyrin.

Authors:  Yoshiko Ohgari; Yuki Nakayasu; Sakihito Kitajima; Mari Sawamoto; Hajime Mori; Osamu Shimokawa; Hirofumi Matsui; Shigeru Taketani
Journal:  Biochem Pharmacol       Date:  2005-11-10       Impact factor: 5.858

7.  Active and higher intracellular uptake of 5-aminolevulinic acid in tumors may be inhibited by glycine.

Authors:  S Langer; C Abels; A Botzlar; S Pahernik; K Rick; R M Szeimies; A E Goetz
Journal:  J Invest Dermatol       Date:  1999-05       Impact factor: 8.551

8.  The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action.

Authors:  Goldie Y L Lui; Peyman Obeidy; Samuel J Ford; Chris Tselepis; Danae M Sharp; Patric J Jansson; Danuta S Kalinowski; Zaklina Kovacevic; David B Lovejoy; Des R Richardson
Journal:  Mol Pharmacol       Date:  2012-10-16       Impact factor: 4.436

9.  Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment.

Authors:  Jun Yuan; David B Lovejoy; Des R Richardson
Journal:  Blood       Date:  2004-05-18       Impact factor: 22.113

10.  Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents.

Authors:  Danuta S Kalinowski; Yu Yu; Philip C Sharpe; Mohammad Islam; Yi-Tyng Liao; David B Lovejoy; Naresh Kumar; Paul V Bernhardt; Des R Richardson
Journal:  J Med Chem       Date:  2007-06-30       Impact factor: 7.446

View more
  11 in total

1.  The effect of iron ion on the specificity of photodynamic therapy with 5-aminolevulinic acid.

Authors:  Maiko Hayashi; Hideo Fukuhara; Keiji Inoue; Taro Shuin; Yuichiro Hagiya; Motowo Nakajima; Tohru Tanaka; Shun-ichiro Ogura
Journal:  PLoS One       Date:  2015-03-30       Impact factor: 3.240

2.  Synthesis of New Styrylquinoline Cellular Dyes, Fluorescent Properties, Cellular Localization and Cytotoxic Behavior.

Authors:  Marzena Rams-Baron; Mateusz Dulski; Anna Mrozek-Wilczkiewicz; Mateusz Korzec; Wioleta Cieslik; Ewelina Spaczyńska; Piotr Bartczak; Alicja Ratuszna; Jaroslaw Polanski; Robert Musiol
Journal:  PLoS One       Date:  2015-06-26       Impact factor: 3.240

3.  Exploring the anti-cancer activity of novel thiosemicarbazones generated through the combination of retro-fragments: dissection of critical structure-activity relationships.

Authors:  Maciej Serda; Danuta S Kalinowski; Nathalie Rasko; Eliška Potůčková; Anna Mrozek-Wilczkiewicz; Robert Musiol; Jan G Małecki; Mieczysław Sajewicz; Alicja Ratuszna; Angelika Muchowicz; Jakub Gołąb; Tomáš Simůnek; Des R Richardson; Jaroslaw Polanski
Journal:  PLoS One       Date:  2014-10-16       Impact factor: 3.240

4.  Iron Chelators and Exogenic Photosensitizers. Synergy through Oxidative Stress Gene Expression.

Authors:  Anna Mrozek-Wilczkiewicz; Katarzyna Malarz; Marzena Rams-Baron; Maciej Serda; Daniela Bauer; Franz-Peter Montforts; Alicja Ratuszna; Thomas Burley; Jaroslaw Polanski; Robert Musiol
Journal:  J Cancer       Date:  2017-07-05       Impact factor: 4.207

5.  Piperazinyl fragment improves anticancer activity of Triapine.

Authors:  Marta Rejmund; Anna Mrozek-Wilczkiewicz; Katarzyna Malarz; Monika Pyrkosz-Bulska; Kamila Gajcy; Mieczyslaw Sajewicz; Robert Musiol; Jaroslaw Polanski
Journal:  PLoS One       Date:  2018-04-13       Impact factor: 3.240

6.  The role of oxidative stress in activity of anticancer thiosemicarbazones.

Authors:  Katarzyna Malarz; Anna Mrozek-Wilczkiewicz; Maciej Serda; Marta Rejmund; Jaroslaw Polanski; Robert Musiol
Journal:  Oncotarget       Date:  2018-04-03

7.  The Forty-Sixth Euro Congress on Drug Synthesis and Analysis: Snapshot .

Authors:  Pavel Mucaji; Atanas G Atanasov; Andrzej Bak; Violetta Kozik; Karolina Sieron; Mark Olsen; Weidong Pan; Yazhou Liu; Shengchao Hu; Junjie Lan; Norbert Haider; Robert Musiol; Jan Vanco; Marc Diederich; Seungwon Ji; Jan Zitko; Dongdong Wang; Danica Agbaba; Katarina Nikolic; Slavica Oljacic; Jelica Vucicevic; Daniela Jezova; Anna Tsantili-Kakoulidou; Fotios Tsopelas; Constantinos Giaginis; Teresa Kowalska; Mieczyslaw Sajewicz; Jerzy Silberring; Przemyslaw Mielczarek; Marek Smoluch; Izabela Jendrzejewska; Jaroslaw Polanski; Josef Jampilek
Journal:  Molecules       Date:  2017-10-28       Impact factor: 4.411

8.  Design and synthesis of anticancer 1-hydroxynaphthalene-2-carboxanilides with a p53 independent mechanism of action.

Authors:  Ewelina Spaczyńska; Anna Mrozek-Wilczkiewicz; Katarzyna Malarz; Jiri Kos; Tomas Gonec; Michal Oravec; Robert Gawecki; Andrzej Bak; Jana Dohanosova; Iva Kapustikova; Tibor Liptaj; Josef Jampilek; Robert Musiol
Journal:  Sci Rep       Date:  2019-04-23       Impact factor: 4.379

9.  Iron and Copper Intracellular Chelation as an Anticancer Drug Strategy.

Authors:  Kavita Gaur; Alexandra M Vázquez-Salgado; Geraldo Duran-Camacho; Irivette Dominguez-Martinez; Josué A Benjamín-Rivera; Lauren Fernández-Vega; Lesly Carmona Sarabia; Angelys Cruz García; Felipe Pérez-Deliz; José A Méndez Román; Melissa Vega-Cartagena; Sergio A Loza-Rosas; Xaymara Rodriguez Acevedo; Arthur D Tinoco
Journal:  Inorganics (Basel)       Date:  2018-11-30

10.  Broaden sources and reduce expenditure: Tumor-specific transformable oxidative stress nanoamplifier enabling economized photodynamic therapy for reinforced oxidation therapy.

Authors:  Xiaoyu Xu; Binyao Huang; Zishan Zeng; Jie Chen; Zeqian Huang; Zilin Guan; Meixu Chen; Yanjuan Huang; Chunshun Zhao
Journal:  Theranostics       Date:  2020-08-21       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.